Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.55 |
| ▸ | ITGAV | P06756 | 1/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.55 |
| ▸ | TPH1 | P17752 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932906 | 1.00 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL169646 | 1.00 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL31370437 | 0.95 | SLC7A5 (0.56) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL180331 | 0.87 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL180332 | 0.87 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL289162 | 0.87 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL8423623 | 0.87 | SLC7A5 (0.57) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL4943107 | 0.86 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL30037334 | 0.86 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL3059437 | 0.86 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024121249-A1 | ALPHA EMITTER LABELLED SOMATOSTATIN RECEPTOR ANTAGONISTS | ARICEUM THERAPEUTICS GMBH (DE) | 2024-06-13 | — | — | WO | claimed |
| EP-2801582-B1 | Somatostatin receptor 2 antagonists | SALK INST FOR BIOLOGICAL STUDI (US) | 2017-09-06 | — | — | EP | claimed |
| EP-2383289-B1 | Receptor (SSTR2)-selective somatostatin antagonists | SALK INST FOR BIOLOGICAL STUDI (US) | 2014-10-08 | — | — | EP | claimed |
| EP-2433963-B1 | Receptor (SSTR2)-selective somatostatin antagonists | SALK INST FOR BIOLOGICAL STUDI (US) | 2014-06-04 | — | — | EP | claimed |
| EP-2076535-B1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | SALK INST FOR BIOLOGICAL STUDI (US) | 2013-03-06 | — | — | EP | claimed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2025-12-02 | — | — | US | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-4630064-A1 | ALPHA EMITTER LABELLED SOMATOSTATIN RECEPTOR ANTAGONISTS | Ariceum Therapeutics GmbH (DE) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024254339-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024252336-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | PEPTIDREAM INC. (JP) | 2024-12-12 | — | — | WO | disclosed |
| US-20090203622-A1 | METHOD OF TREATING METASTATIC STAGE PROSTATE CANCER | FERRING INTERNATIONAL SA. | 2009-08-13 | — | — | US | disclosed |
| US-20090203623-A1 | METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST | FERRING INTERNATIONAL SA | 2009-08-13 | — | — | US | disclosed |
| EP-2076535-A2 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20080299040-A1 | SOMATOSTATIN RECEPTOR 2 ANTAGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES UNIVERSITAT BERN UNIVERSITY HOSPITAL BASEL | 2008-12-04 | — | — | US | disclosed |
| US-20080260638-A1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008048942-A2 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2008-04-24 | — | — | WO | disclosed |
| US-6875843-B2 | Prevention of diabetes and prolongation of the honeymoon phase of diabetes by administration of GnRH antagonists | CHILDREN'S MERCY HOSPITAL (US) | 2005-04-05 | — | — | US | disclosed |
| US-20030045475-A1 | Prevention of diabetes and prolongation of the honeymoon phase of diabetes by administration of GnRH antagonists | JACOBSON JILL D (US) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260638-A1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | SSTR5, SSTR4, SSTR3 | SLC7A5 85/4885PTGS1 4381/4885ALPI 4180/4885 |
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | SLC7A5 1032/4885PTGS1 2711/4885ALPI 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.